Member Info for pickedpeck

Estimating the value of the glaucoma market for SIRT6-based treatment requires looking at it through two lenses: the Total Addressable Market of current glaucoma therapies and the disruptive premium of neuroprotection.

The current data suggests that Genflow is attempting to create a new, high-value category within the Glaucoma market.

1. The Global Market Context (2026–30)

The glaucoma market is vast but currently dominated by symptom management (eye drops to lower pressure).

Market Size: The global glaucoma therapeutics market is valued at approximately $7.5 billion in 2026 and is projected to reach $11–$14 billion by the early 2030s.

Growth Driver: This 6.5% CAGR is driven by an aging global population. By 2030, an estimated 110m people worldwide will have glaucoma.

The Gene Therapy Segment: Within this, the Ophthalmic Gene Therapy sector is the fastest-growing sub-segment, expanding at a CAGR of roughly 19%.

2. The Neuroprotection Value Multiplier

Current treatments (prostaglandins, beta-blockers) only address IOP (Intraocular Pressure). They don't stop the underlying death of retinal ganglion cells.

Unmet Need: Approximately 15–20% of patients continue to lose vision despite having controlled eye pressure.

SIRT6 Positioning: Genflow’s GF-4001/GF-1002 variant is being positioned as a first-in-class neuroprotective. In biotech a drug that prevents cell death typically commands a 3x to 5x price premium over drugs that merely manage symptoms.

If a SIRT6 treatment captured just 5% of the "refractory" glaucoma market (those failing standard drops), it would be addressing a multi-billion dollar niche.

3. Estimated Value of the SIRT6 Opportunity

Based on corporate signals and analyst models for 2026:

Peak Sales Potential: For a successful neuroprotective gene therapy in the eye, analysts often model peak annual sales (Blockbuster status) of $1.5 to $2.5Bn.

Valuation of the Asset: For a company like Genflow a successful PoC in the eye (expected to be announced at the AAO in October 26) could theoretically re-rate the glaucoma program alone at several multiples of the current company mkt cap.

4. Acuitas Advantage

The use of LNPs for the eye is a critical value driver:

LNPs are significantly cheaper to manufacture than viral vectors (AAV) and, unlike AAV, LNPs can be administered multiple times. In a market like glaucoma, where patients may need decades of support, the recurring revenue model of a re-doseable LNP SIRT6 treatment is significantly more valuable to a Big Pharma partner than a one-and-done viral shot.

The Bottom Line

We are looking at a $12B+ opportunity by 2030. If Genflow presents data at the AAO in October showing that SIRT6 actually protects the optic nerve they aren't just competing with eye drops, they are competing for the entire neuroprotection crown which currently has no approved pharmaceutical incumbent.

There have been a few posts lately focusing on the SLAB trial and the possibility that it it is successful it will lead to a very profitable partnership with an animal health company. All of which is true and good, and makes the company a lot more valuable than today.

But, with all due respect to dog owners, vets, canine enthusiasts and the Crufts committee... It's not at all what this is about.

The SLAB trial is the first time SIRT6 epigenetic treatment has been tried in a large mammal. In most research work there are huge functional gaps where treatments fail, between the lab bench and the mouse, between the mouse and the dog, and between the dog and the human. In this case the SIRT6 originated in humans, it's actually more of a surprise that it also works in mice and dogs, and if so is very likely to work in humans.

So the dog trial is important not just for animal health potential, but as a bridge to the treatment being tried on and working in humans. Human health as a market utterly dwarves animal health.

The diseases that could potentially be treated with SIRT6 are individually hugely valuable.

Glaucoma - blindness caused by degradation of retinal nerves due to excess pressure in the eye. No current cure, rather ineffective mitigation. Potential for prevention of macular degeneration.

Sarcopenia - side effects of GLP1s like Wegovy, Mounjaro etc, muscle wasting in the elderly, adjust disease to osteoporosis, no current cure or even effective treatment.

Late stage MASH - the last stage of liver disease before liver cancer. Only current cure is a risky and expensive transplant.

Werner Syndrome - rare disease of premature aging, no current cure or effective treatment.

In 2024 and 25 Genflow were focused on MASH, but in 2026 have pivoted somewhat to the shorter lead time and lower cost options of glaucoma and sarcopenia.

I think it's important to understand exactly what this pivot means, so I am going to put up a subsequent post about the Glaucoma and Sarcopenia markets.

The real trick though, and the multiplier value , I'd that each of these disease areas demonstrates SIRT6 in a different systemic context: Muscle (MSK), CNS, Organs. It shows that SIRT6 can work on a portfolio of diseases issues and not be blocked by being characterised as a longevity product. That increases the overall value exponentially.

Why the UCLA Clock is the 'Digital Audit' of Genflow’s SIRT6 mRNA

We’re all waiting on the UCLA data RNS, hopefully due imminently, but the actual technicals of why this RNS will be the defining moment for Genflow’s valuation are relatively easy to understand. This isn't a "subjective" health check; it's a digital audit of the dogs' DNA.

1. The Mechanics: What is a 'CpG Site'?

The Horvath Clock (the one UCLA uses) looks at 353 specific "CpG sites" on the DNA.

A CpG site is just a spot where a Cytosine is next to a Guanine.

As we age, our body adds "Methyl groups" to these sites (like rust on a hinge).

The SIRT6 Factor: We know SIRT6 is the "Master Optimizer." It regulates Histone Deacetylation. In simple terms: SIRT6 clears the "rust" (methyl groups) and keeps the DNA "software" from glitching.

2. How UCLA Measures 'Success'

UCLA uses Elastic Net Regression (a high-level AI algorithm) to compare the methylation levels of the SIRT6-treated dogs against the control group.

The 'Delta': They are looking for Epigenetic Age Acceleration (EAA).

If the SIRT6 group has a lower EAA than the controls, Genflow has mathematically proven that their mRNA treatment is reprogramming the cells to a more youthful state.

3. Decoding the P-Values (The Math of Certainty)

When the RNS lands, the p-value is your most important number. It tells you the statistical significance of the SIRT6 effect:

p < 0.05 (Standard): 95% certainty the SIRT6 caused the age reversal. This is the "Minimum Viable Product" for an FDA/EMA human trial.

p < 0.01 (High): 99% certainty. This is where Big Pharma (Lilly, Novo) starts paying attention to the data rooms.

p < 0.001 (Institutional): 99.9% certainty. This suggests a massive "Effect Size." If we see this, the Acuitas partnership starts to look like a bargain for Acuitas.

4. Why the 'Sarcopenia' Patent Matters Now

The patent filed on April 13th wasn't random. It focuses on the "altered endocrine function" of the muscle. This implies that the histology (tissue) data from the dogs showed muscle repair that perfectly matches the methylation (clock) data.

Summary:

We aren't just looking for "healthier dogs." We are looking for a statistical divergence in the DNA methylation of 353 specific sites. If UCLA confirms that p < 0.05, Genflow is a validated Epigenetic Reprogramming platform.

I've bought quite a few more today across several trades, I see the Acuitas deal as the next level of external validation of the tech and can't see how it won't be more widely picked up now given their industry profile.

Just to add a little to the Acuitas story...

Acuitas is a private, multi-billion dollar entity that does not need Genflow’s money. In fact, the RNS explicitly states the deal is fully funded by Acuitas.

What they saw: Acuitas likely conducted a "Technology Evaluation Assessment" (their standard pre-partnership move). They would have tested Genflow’s SIRT6 mRNA in their proprietary LNPs to check for stability, expression, and toxicity.

The Inference: Acuitas does not partner with "science projects." If they are footing the bill for the formulations, their internal data likely shows that Genflow’s SIRT6 is highly potent and technically compatible with industrial-scale delivery. They are essentially betting their reputation on SIRT6 being the next breakthrough.

This is a huge independent external validation.

I was buying some more this morning and it went briefly n/t for even small amounts. It suggests the MMs don't have a huge bundle of stock to hand, or a seller on the shelf anymore holding the price down.

If some braver US biotech buyers start following the story and picking up some volume things could change pretty quickly.

At some point we may also get some analyst coverage too which helps push the company profile, even if they don't normally know ass from elbow.

Plus obvs the Bloom Burton thing tomorrow, can't imagine Tom Madden not mentioning Genflow at all, and there will be some industry heavyweights there that may decide picking up a position here at whatever price is a good idea.

I'm trying to hold back hyperbole pretty hard, but seriously, how much validation does the market need before realising this is real?

The timing of today's RNS is no coincidence. Tom Madden (CEO of Acuitas) is presenting at the Bloom Burton & Co. Healthcare Investor Conference in Toronto tomorrow (April 21, 2026).

The Narrative Shift: In their pre-conference materials (April 13), Acuitas explicitly mentioned their focus on "Extrahepatic" (outside the liver) and "Epigenetic" medicines.

The Connection: Genflow’s SIRT6 mRNA for the Eye (Glaucoma) and Muscle (Sarcopenia) fits perfectly into Acuitas’ stated goal of moving beyond the liver. Tom Madden is effectively out there selling the "delivery solution" while Genflow is providing the "miracle payload."

The Biotech Trade Press (BioSpace, Investing.com, Share Talk) has been very specific about the "Acuitas Effect."

​Investing.com & Reuters: Highlighted the 11.1% jump today, framing it as a "Strategic Technology Collaboration." They emphasized that it is fully funded by Acuitas, which is a rare and powerful signal.

​BioSpace: Released a detailed piece today noting that Acuitas’ decision to invest its own resources into formulating Genflow’s SIRT6 is a "meaningful and independent validation."

​The Global Peer Group: M2 Pharma just reported (April 15) that Circio Holding also partnered with Acuitas. This shows Acuitas is currently "hand-picking" a new cohort of next-gen RNA companies. Genflow is now officially in that elite "Acuitas Club."

Last chance to buy your tickets at this discounted price.

This is not a dog longevity day dream company. This is the next mRNA biotech power house with a platform solution for key age related human diseases.

Ok, apologies all, I have woken up now. Long weekend, long story.

Soo... This. Where do you start. All our posts so far are massively understating how important this is. I'd suggest more than the patents dropping, more than methylation clock data.

This RNS is arguably the most significant "validation event" in the company's history. By securing a partnership with Acuitas Therapeutics, Genflow has effectively moved from the "science experiment" phase into the "industrial-grade biotech" phase.

Acuitas is not just a partner; they are the gold standard for delivery. Their Lipid Nanoparticle (LNP) technology is the "engine" inside the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) and Alnylam’s Onpattro.

Gad Berdugo’s "Acuitas Connection"

While Gad hasn't held a role at Acuitas, his career as a Chief Business Officer (CBO) at Editas Medicine and his background in investment banking (Lazard) means he has been operating in the exact "deal-making circle" where Acuitas is the primary gatekeeper.

Editas is a pioneer in CRISPR gene editing. In the world of gene therapy, if you want to deliver a payload (like CRISPR or Genflow’s SIRT6 mRNA) to a specific part of the body, you have two choices: Viral (AAV) or LNP. Gad’s tenure at Editas coincided with the industry’s massive pivot toward LNPs. This deal has "Gad" written all over it.

Acuitas rarely works with micro-caps. They usually only partner with companies where the science is so compelling that they are willing to fully fund the initial formulations themselves. This suggests Gad used his US institutional network to bypass the usual "pay-to-play" barriers and secure a deal that is entirely non-dilutive.

Acuitas is known as the "Kingmaker" in biotech. When they partner, the target company often sees an astronomical re-rating.

Alnylam : Partnered with Acuitas for LNP delivery. Led to Onpattro, the first FDA approved mRNA drug. Alnylam is now a $20Bn giant.

BioNTech : The COVID vaccine distributed by Pfizer used Acuitas LNP delivery. BioNTech is now a $30Bn company.

Intellia Therapeutics: Acuitas style LNP for CRISPR in the liver. Led to the first successful in human gene editing, mkt Cap peaked at over $10Bn.

Acuitas is a private, multi-billion dollar entity. They don't need Genflow's money. The fact that they are investing their own resources to formulate Genflow’s SIRT6 means they have likely seen the "Sarcopenia" and "Glaucoma" lab data we discussed and believe the SIRT6 mRNA payload is a "blockbuster" asset.

To present at AAO in October, Genflow needs high-quality, stable formulations. By using Acuitas LNPs, Dr. Leire can walk onto that stage and say, "Our SIRT6 works, and it is delivered by the most clinically validated system on the planet." This removes the "delivery risk" which is the number one reason gene therapy deals fail.

In short, today, Genflow became a legitimately backed mRNA player.

Let's hope everyone feels the same 😁

Marty, think of this like Genflow has an idea for a great sandwich with a fabulous filling that everyone will want, but we don't make bread.

The world's best baker has just agreed to let us use all the bread we want free of charge to develop our sandwich, because they believe our filling will be awesome too.

When we come to sell our sandwiches the baker will benefit by selling their bread wrapped around our filling, and no matter whether we sell as M&S or Sainsbury's branded sandwiches our content and their bread will still be there.

It's good to remember that without bread there is no sandwich, but also without filling it's just bread.

To stretch the analogy to the limit, before we had the idea to put the filling in a sandwich out only option was to serve it as a seven course dinner that took hours and huge expense to prepare and serve.

Great news, no ifs or buts. Should accelerate all clinical programs, and shows growing belief in the technology behind SIRT6.

Moneymunch,

I didn't say the patent wasn't valuable or useful, it absolutely is, but the share price moves on buys and sells and the whim of the market makers, not the intrinsic underlying value of the company and it's IP assets.

Acquisitions include valuations for (proven) IP, but the open stock market is irrational, evidenced by the current share price.

The question is which funds or retail investors will buy on the basis of the patent being granted rather than pending, and which of those would be more or less likely to buy based on evidence which backs the claims in the patents?

There is a real difference in the value of an unproven claim in a granted patent Vs a patented claim that is backed by experimental data and proven to be true.

Moneymunch,

I don't see the patent drop as immediately transformative for the SP. I do not think anyone is waiting to buy based on that, any serious investors know the patent will now almost inevitably be granted, the likely period for protests or complaints, or for the examiner to claim preemption, has passed. I also don't think the MMs will rerate based on the patent. The intrinsic value is increased for acquisition, but until those negotiations it may be a useful thing to know but not much else.

Having said that I do think there will be wording in the animal health partnership negotiation and contracts related to the patents and it may affect the valuation and payments. This also affects any future human contracts related to the patent lodged last week.

In particular there may be:

Contingent Royalty Tiers: It is common to see a "pre-grant" royalty rate and a "post-grant" royalty rate. The partner pays a lower rate (or just R&D milestones) while the patent is pending, which steps up once a Valid Claim is issued.

​Prosecution Control: The contract will specify who controls the "prosecution" (the back-and-forth with patent examiners). Usually, Genflow retains control to ensure the patent isn't narrowed too much, but the partner may have "review and comment" rights since they are paying for the exclusivity.

​Retroactive Payments: Some "reach-back" clauses may allow Genflow to collect higher royalties retroactively for the period between the patent's publication and its actual grant, provided the issued claims are substantially similar to the published ones.

It may all be moot if the patents are granted prior to the contract being signed obviously, but it is also possible that one of the majority animal health companies could try and gain some cheaper commercial pre-emption by signing ahead of the grant.

On the other hand I do think there may be some eyes on the initial methylation clock data which is also due to be released imminently. That potentially makes the claims in the foundation patent very real.

Marty,

There is only one product with patents (claims) for use in several different contexts. There is no separate dog product, there is only a license to use the SIRT6 product in the specific (animal) context.

The form of the license deal is what is negotiable. It could be a one time payment for an open ended license to use SIRT6 in all non human applications. With so much potential that form of deal is unlikely and not especially in Genflow's interest, but would bring in the most short term money.

Or it could be an up front fee plus royalty payments, or it could even be structured as an up front fee plus commercial milestone payments, either of which could generate more money long term as the products derived from the license reach the market.

It may be some other form of structure, there are many possibilities and the company has not really shared anything on the details. Loose talk of a 'sale' is about one of these types of license deals.

Last thing, a license like this will transfer a controlled amount of IP to the buyer, for example the dosing and lab results information and manufacturing processes.

One last point for the weekend. The fact I can put those numbers out there with a straight face shows how mispriced the market currently has this. Those numbers are far from impossible, and may even be pretty low depending how far they get with the program before being acquired.

Just for a basic perspective when Genflow was first listed as an i.p.o. in January 2022 it's share price was 8p per share and estimated mkt cap of £23.5m, dilution since has raised funds for research, there were 293m shares floated originally. However that is still double the mkt cap for today, and all they had in hand then were a few lodged patents and a nice sounding idea. It's been a bad few years for biotechs in general, and Genflow value fell to cash in hand and being priced for bankruptcy.

Four years further on they have a lot more progress under their belt, and are about to publish data from the SLAB trial.

Even if the data from that shows no significant reversal of the methylation clock, but the data in full shows a worthwhile increase in muscle mass and mitochondrial activity (as indicated in the Oxford talk video) it is still extremely valuable, but add in any independently measured clock reversal and the value expands exponentially. The relative value of a lodged patent Vs experimental data ? Should be 3 or 4 to 1 as an absolute minimum.

So what should the market cap be right now? There is literally nothing priced in for any of the potential.

I suspect the way this will play out will be roughly this:

Post dog study, an initial animal health partnership with an up front payment i.r.o. $25m . Timing June / July ish .

That money used to accelerate a three pronged human program on MASH, Sarcopenia, and Glaucoma. I believe the latter two are products of Gad Berdugo joining and bringing commercial focus and LNP experience and will be the quicker value drivers.

Glaucoma reveal of lab work and program design in New Orleans AAO conference October 26. Should create a huge splash, there is no competing therapy with similar promise. I suspect the intent is to attract a blue chip opthalmology partner for development, but with some smaller chances of acquisition. May also be twinned with a NASDAQ listing as with money and a focused program they won't just get swallowed and disappear.

Sarcopenia will be an accelerated program following the dog study. The fact it's the big GLP1 side effects mitigation offers huge potential, but the aging market for MSK is also a huge potential opportunity. This once designed as a clinical program may increase the potential for acquisition.

Both Glaucoma and Sarcopenia initial human clinical programs can be executed very quickly, 6-9 months for initial results possibly. The company with data from both in hand is a compelling acquisition target for big pharma.

I can't see them staying independent long enough to get the MASH program underway, it's a big market with unmet need and has a high value itself, but is slow, expensive and complicated to put through a clinical trial program.

Timing for acquisition I would guess H1 2027, with the various valuation catalysts creating a series of value step changes along the way.

Animal Health partnership : sp ~ 6-12p, maybe more as it signals belief in the tech.

Opthalmology data : sp 10-20p, maybe more as if it works it's a massive breakthrough.

Opthalmology development partnership : 15-30p minimum, again a signal on the tech.

Sarcopenia data : 30-50p+ and rising fast as it will be combined with opthalmology.

NASDAQ listing 40-70p entry

Acquisition auction: with data in hand from two TAs, almost any figure but I'd guess a minimum of 90p.

Obviously wild assed guesses, but there is no biotech with the same potential for a platform play and pipeline in a box with even remotely the same impact. With data from two TAs this becomes a golden ticket and there will be a very disorderly queue.

The company shareholder structure has the ability to resist early low ball plays, so they may hold out to get the maximum platform value which would be late 2027.

Phase 1/2 data from both opthalmology showing ganglion preservation and (drum roll) regrowth implying CNS and nerve damage repair - astronomic valuation on its own.

Phase 1/2 data from Sarcopenia (GLP1s, aging) and frailty (osteoporosis adjunct) - astronomic value on its own.

Eric Leire has described 2026 as a year of catalysts, it certainly looks th

Some other useful bits from the video...

Scientific data in the video supporting the pivot to glaucoma and sarcopenia is primarily based on the role of the SIRT6 gene and its centenarian variant in trials and lab work to date. Research indicates that SIRT6 acts as an upstream regulator for multiple aging-relevant mechanisms, making it a viable target for these conditions.

Data Supporting Glaucoma Treatment:

The shift toward glaucoma research is driven by the need for neuroprotection of retinal cells rather than just managing intraocular pressure:

Mechanism of Action: SIRT6 has been shown in studies (including research from Texas University and Japanese papers) to preserve ganglion cells in the retina [49:49].

Delivery and Safety: Preclinical data using Lipid Nanoparticles (LNPs) demonstrated that the treatment safely expresses SIRT6 in the ganglion cells of the eye [50:08].

Clinical Need: It addresses the second leading cause of blindness by preventing the destruction of the optic nerves [49:33].

Data Supporting Sarcopenia Treatment

Sarcopenia (age-related muscle loss) is targeted because it is a major driver of frailty and mortality:

Mice Study Data: In a study involving 18-month-old mice (equivalent to 60-year-old humans), the centenarian SIRT6 variant produced a statistically significant improvement in a 34-criteria frailty index [33:34].

Dog Clinical Trials: The "Slab" clinical trial involving 24 aged beagles showed consistent positive responses in treated arms for endpoints including muscle mass (measured via echography) and mitochondrial function in muscle biopsies [34:07], [01:23:34]. *** - This is big news related to GLP1 side effects

Biological Age Reversal: Using DNA methylation clocks (the "Horvath clock"), researchers observed a decrease in biological age in overexpressed mammal cells, suggesting a reversal of aging rather than just a slowing [32:15]. *** - Also pretty damn big news.

The SIRT6 Centenarian Variant

The specific scientific "pivot" relies on a variant of SIRT6 found in people who live over 100 years. This variant is two amino acids different from the wild type and has shown a significantly higher ability to:

Repair DNA damage [25:40].

Provide antifibrotic and anti-inflammatory effects [25:50].

Regulate epigenetic stability [29:43].

This data is currently being used to transition from preclinical models to clinical applications in both veterinary and human medicine.

If you're new to all this Genflow / longevity / beagles / glp1 side effects/ glaucoma malarkey then this rather lengthy video of Dr Eric Leire presenting to Oxford Uni in Feb should help you catch up and then some.

https://youtu.be/ZddAjdYwDl0

Even though it's the weekend I am sure some of you will have other priorities than watching a feature length Genflow film, so here is a bit of a summary of some key points that help 'the too good to be true' narrative be put to bed.

This is Dr. Eric Leire’s presentation to the Oxford Society of Ageing and Longevity (OSAL), in February 2026. This was a critical "unblinding" period for the company's research.

​1. Tone and Body Language Analysis

​Dr. Leire’s presentation style is notably informal and academic rather than a polished corporate pitch. He leans into his identity as a "serious" scientist and physician. He shows high physical engagement when discussing the centenarian variant [26:00], often using hand gestures to explain the DNA repair mechanism. However, he is visibly more relaxed when introducing Sophie Mano, the researcher who led the dog study [27:30].

​2. Potential Collaborations on the SLAB Trial

​

The video reveals significant details about how the SLAB (Sarcopenia and Longevity in Aged Beagles) trial was constructed through a network of partners:

​University of Rochester (New York): Dr. Leire credits Vera Gorbunova and her work on SIRT6 in rodents as the scientific bedrock for the trial [22:49]. The preliminary aged-mice frailty studies were conducted in collaboration with her lab [32:41].

​

Duke University: During the Q&A, Leire reveals a collaboration with Matthew [Kaeberlein] or his associates at Duke to use AI and machine learning to optimize clinical trial designs, specifically for their MASH and potentially longevity protocols [01:32:08].

​UCLA (Steve Horvath/Epigenetic Clock): The trial used the Horvath/Greenage methylation clock to measure biological age. Leire mentions that the blood samples from the SLAB trial were sent specifically to UCLA for the "grand reveal" of the methylation age results [36:12].

​

Dely Genetics (Belgium): He mentions working with Cedric Spir, the former "plasmid guy" for GSK, to manufacture the naked DNA used in the trial’s active arms [39:30].

​

The "Independent CRO": While the specific name isn't mentioned, Sophie Mano notes they reached out to 32 different Contract Research Organizations (CROs) before finding one capable of sourcing 24 identical, aged beagles.

Key Scientific Takeaways

Naked DNA vs. AAV: One of the biggest "reveals" in this talk is that naked DNA (which is cheaper and easier to transport) yielded results consistent with the more expensive AAV (viral vector) delivery [40:18].

Safety: The trial was randomized and blinded. They confirmed that only one dog died during the study, and it was later revealed to be in the control group, which was a major relief for the company’s safety profile [37:56]

Offgrid,

Thanks! This is kind of my home territory for once, although I have had a pretty varied career.

The most frustrating thing about small bios is that you can literally go years with seemingly nothing happening, and then it all kicks off at once. They are impossible to trade, you have to invest with some sort of conviction and wait. That's what I've done, I am pretty heavily bought in now and will be waiting for the coming transactions, even though I think this year will likely be one or two partnerships and any acquisition may be well into next year.

Having said that the imminent news on biopsies could carry a lot of weight given the huge associated potential, and the AAO slot could even be potentially bigger news as it moves the company from muscle to CNS.

We have arrived at the start of the exciting period for this company.

Most people think muscle is just about strength, but there is a lot more to it than that.

These claims prove Genflow is targeting systemic metabolism. That matters a lot, and is the key thing we need to look for when the histology data from the SLAB trial is shared. Here's why:

Claim 0025: The "Muscle-as-an-Organ"

The Text: Refers to the restoration of the endocrine, paracrine, and autocrine function of the muscle.

What it means in English: Muscle isn't just a pulley for your bones; it's a chemical factory. Healthy muscle secretes hormones called Myokines.

The So What?: When we age (or take GLP-1s), the hormone "factory" shuts down. Claim 0025 says SIRT6 variants "re-start" the factory. Those myokines then travel to the brain (improving alertness), the heart (protecting against failure), and the liver (burning fat). The muscle is not just stronger, it is in effect 'younger' and more productive again.

Genflow's patent claim is that it is building a biological 'software update' that makes your body's biggest organ start protecting you again. This is why the dogs in the SLAB trial have better coats and alertness—it’s a systemic and sustained "re-tuning" caused by the muscle.

Claim 0048: The "Regulatory & Partnering" Claim

The Text: Covers the specific pharmaceutical compositions (like the LNP or mRNA delivery) for treating Frailty and Sarcopenia.

What it means in English: This is the Commercial Moat. It protects the how and the what.

The So What?: Claim 0048 is what makes the company buyable. If UCB, Novo or Lilly want to treat muscle loss with a SIRT6 variant, they must pay Genflow to use the method protected in this claim.

This claim is the 'toll booth.' Anyone who wants to enter the $100B obesity-adjunct or sarcopenia market via SIRT6 has to pay the Genflow toll.

In short every single person on a GLP-1 like Ozempic/Wegovy is currently losing 25-40% of their weight from muscle loss or sarcopenia. GLP-1 drugs also cause associated "metabolic suppression" through muscle hormone production loss. SIRT6 variants are the only tech aiming to restore genomic stability in the muscle while the weight comes off. This if proven makes Genflow a "Must-Have" bolt-on for Big Pharma.

So Claim 0025 if validated by the SLAB trial biopsies shows Genflow is the only company with the key to stopping that metabolic side effects disaster.